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Abstract.  The interactions between transferrin (Tf) 
and transferrin receptor (Tfr) as they occur during 
biosynthesis were studied in the human hepatoma cell 
line HepG2,  which synthesizes both.  Early during bio- 
synthesis the Tfr monomer is converted to a  disulfide- 
linked Tfr dimer. The Tfr monomer is not able to 
bind Tf, but Tf binding is observed as soon as the 
covalent Tfr dimer is formed and can take place in the 
ER.  The Tf-Tfr complex is transported through the 
Golgi reticulum and trans-Golgi reticulum (TGR) and 
is ultimately delivered to an acidic compartment, 
where Tf releases its Fe  3÷. We did not observe conver- 
sion of Tf to apoTf in the TGR,  showing that the part 
of the TGR passed by secreted Tf has a pH higher 
than 5.5. 
We conclude that when a  ligand-receptor combina- 
tion is synthesized by one and the same cell, ligand 
and receptor can interact during biosynthesis and be 
transported to the cell surface. 
I 
NTERACTIONS of ligands with receptors are essential in 
the communication of cells with their surroundings, and 
furthermore supply the cell with nutrients. When a cell 
produces both a soluble polypeptide ligand and its receptor, 
they usually follow the same biosynthetic route. Examples 
of receptors and corresponding ligands synthesized by the 
same cell include the couples IL-2/IL-2 receptor, transfer- 
rin/transferrin  receptor  (Tf/Tfr),  1 apolipoprotein  E/LDL 
(ApoE/LDL) receptor, and transforming growth factor or/ 
epidermal  growth factor receptor  (TGFc~/EGFR)  (for re- 
views see references 5, 7, 17, 22, 33). In principle, the simul- 
taneous production of receptor and ligand can result in their 
binding in the course of biosynthesis. Its consequences may 
be  several, depending on the type of ligand and receptor. 
When the ligand is a growth factor, binding of the ligand to 
its receptor during biosynthesis can result in arrival of the 
ligand-receptor complex at the cell surface, and may pro- 
duce a growth stimulus for the cell. This situation constitutes 
a special case of an autocrine loop: secretion of the other- 
wise  released  growth  factor  is  not  necessary.  Autocrine 
loops have been postulated to operate for TGF,  EGF, and 
PDGF with their respective receptors in different cell lines, 
and figure prominently amongst the models explaining tu- 
mor growth (8). 
When the  ligand supplies  a  cell with certain  nutrients 
(e.g., Tf, LDL), binding of ligand and receptor during bio- 
1.  Abbreviations  used  in  this  paper:  alAT,  alphat-antitrypsin;  apoE, 
apolipoprotein  E; apoTf, apotransferrin;  ASGR, asialoglycoprotein recep- 
tor; dNM, 1-deoxynojirimycin; EGFR, epidermal growth factor receptor; 
1D-IEF, one-dimensional  isoelectric  focussing; NANAse, neuraminidase; 
PDGF,  platelet-derived  growth  factor;  Tf,  transferrin;  Tfr,  transferrin 
receptor; TGFa, transforming growth factor a; TGR, trans-Golgi reticulum. 
synthesis can likewise result in appearance of the complex 
at the cell surface followed by its internalization. The ligand 
will thus be delivered back to the cell from which it origi- 
nated. 
To our knowledge, the interaction of receptors with their 
soluble polypeptide ligands in the course of biosynthesis has 
not been documented. We studied the interactions of IT with 
Tfr during biosynthesis in HepG2 cells, because Tf-Tfr inter- 
actions at the cell surface and during recycling have been par- 
ticularly well defined (1, 7, 14, 17, 35). When Tfbinds to Tfr 
at the cell surface, the Tf-Tfr complex is internalized and ar- 
rives in an acidic endosomal compartment. There Tf releases 
its bound Fe  3+, but the resulting apotransferrin (apoTf)-Tfr 
complex is stable at the resident endosomal pH (pH <5.5). 
The  ApoTf-Tfr complex recycles back to the cell surface 
where it dissociates, because at neutral pH the apoTf-Tfr 
complex is not stable, apoTf is released, and Tfr can then 
start a new cycle (7,  17). 
Ligand-receptor interactions during biosynthesis can be 
studied if such complexes can be isolated. For Tf-Tfr interac- 
tions this can be achieved by coimmunoprecipitation of Tf 
with Tfr, using an anti-Tfr antibody. We show that when the 
Tf-Tfr ligand-receptor combination is synthesized  by one and 
the same cell (HepG2), q~f can interact with Tfr during bio- 
synthesis and the Tf-Tfr complex is ultimately delivered to 
a compartment of acidic pH where Tf releases its Fe  3+. The 
resulting apoTf-Tfr  complex will dissociate at neutral pH. 
The trans-Golgi reticulum (TGR)  does not constitute the 
compartment where Tf is converted to apoTf. 
A ligand-receptor combination that reaches the cell sur- 
face through the biosynthetic route will behave similarly to 
a receptor occupied by ligand added externally. 
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The Journal of Cell Biology, Volume 111, October 1990 1383-1392  1383 Figure 1.  Uptake of proteins secreted by HepG2.  HepG2 cells (two different clones) were allowed to take up secreted proteins,  isolated 
from 35S-labeled  HepG2 cells, for different times indicated in minutes above the gel. Total cell lysates, including bound,  radiolabeled pro- 
teins, were analyzed on SDS-PAGE. Three major proteins bind to HepG2 cells: apolipoprotein E (ApoE) via the apoB/E receptor, albumin 
(Alb),  and transferrin  (Tf) via the transferrin  receptor.  The identity of the proteins indicated,  was established by inununoprecipitation. 
NANAse digestion of the radiolabeled secreted proteins produced by HepG2 virtually abolishes apoE uptake but not Tf uptake.  Note the 
steady-state  levels of bound Tf from  15  min on,  consistent with rapid  recycling of Tfr.  The position of the markers  are indicated. 
Materials and Methods 
Cells and Cell Culture 
The  human  hepatoma  cell  line  HepG2  (18) was  grown  in  DME  sup- 
plemented with  10% (vol/vol) FCS. The human erythroleukemia  cell line 
I(562 (20) was grown in RPMI-1640 supplemented with 10% (vol/vol) FCS. 
Antibodies 
The following antibodies were used. Rabbit anti-human  transferrin  serum 
and rabbit anti-human  al antitrypsin  serum (Central  Laboratories  of the 
Red Cross Bloodtransfusion Centre, Amsterdam, The Netherlands),  mouse 
anti-human  transferrin  receptor  monoclonal  antibody  (66Ig10) (36). 
Gel Electrophoresis 
SDS gel electrophoresis (9) and one-dimensional  isoelectric focussing (1D- 
IEF) (24) were performed  as described.  Gels were fluorographed  using 
DMSO/PPO and exposed on Kodak XAR5 films. 
Preparation of  tW  SIMethionine-labeled 
HepG2 Supernatant 
HepG2 cells were cultured on Ham F-12 medium 20 h before labeling, fol- 
lowed by labeling with [35S]methionine in methionine-free RPMI medium 
for 6 h. The supernatant was removed and concentrated through a Centricon 
30 (Amicon Corp.,  Danvers, MA), followed by removal of free [3SS]methi- 
onine by gel filtration on a PD-10 column in water. The resulting prepara- 
tions were stored at 4°C. 
Neuraminidase treatment of HepG2 supernatants was performed at room 
temperature  using 25 U of neuraminidase  (type V; Sigma Chemical Co., 
St.  Louis,  MO) per nil. 
35  Uptake of[  S]Methionine-labeled Proteins 
HepG2  cells were  plated  in 5-cm  petri  dishes  in  DME plus  10%  FCS. 
HepG2 cells were then exposed for 24 h to serum-free DME supplemented 
with 20 mM Hepes,  10 #M  17-~-estradiol, 30 nM Na-selenite,  40 ng/ml 
dexamethasone,  and 10 v,g/rnl insulin. The cells were washed three times 
with Hank's medium and exposed to l ml of the above described preparation 
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taken at 0,  15, 30, 60, and 120 min. Medium was removed and the cells 
were washed three times at 4°C with PBS (Dulbecco). Cells were then lysed 
in  1 ml NP-40 lysis mix (10 mM Tris-HC1, pH 7.4, 5  mM MgC12, 0.5% 
(vol/vol) NP-40, and 1 mM PMSF). Debris was removed (5 min, 10,000 g) 
and the supernatant was lyophilized. The residue was resuspended in 30 #1 
H20 and 15 #1 2x SDS sample buffer was added. Samples were boiled and 
analyzed by SDS-PAGE on a  10%  gel. 
lmmunoprecipitation  of  Ligand and Receptor 
HepG2 cells were exposed to radiolabeled HepG2 supernatant (containing 
Tf) for 1 h at 0°C in PBS or DME (which contains Fe  3+ that should allow 
loading of apoTf and its conversion to Tf). Nonbound material was removed 
by washing with PBS (three times) at 0°C. 
Cells were then lysed at either pH 5.1  (50 mM  NaAc pH 5.1,  5  mM 
MgCl2 and 0.5 %  [vol/vol]  NP-40) or pH 7.4 (50 mM Tris-HC1 pH 7.4, 
5  mM MgCl2, and 0.5 %  [vol/vol] NP-40).  Tfr and Tfr-Tf were immuno- 
precipitated with the mAb 66Ig10 (36) from lysates prepared at pH 5.1 or 
7.4. Residual Tf was immunoprecipitated with the rabbit anti-human  trans- 
ferrin serum. 
Immunoprecipitates from cells lysed at pH 5.t were washed in 50 mM 
NaAc pH 5.1, 5 mM EDTA, 150 mM NaC1, and 0.5% (vol/vol) NP-40. Im- 
munoprecipitates from cells lysed at pH 7.4 were washed in a solution of 
50 mM Tris-HCl pH 7.4,  150 mM NaCl, 5 mM EDTA and 0.5% (vol/vol) 
NP-40 (NET buffer). Immune complexes were resuspended in SDS sample 
mix, boiled, and analyzed by SDS-PAGE on a  10%  gel. 
Pulse-Chase Experiments 
Pulse-chase experiments were  performed as described  (25).  Binding of 
secreted radiolabeled Tfto HepG2 cells during the chase was prevented by 
inclusion of nonradioactive Tf in the labeling medium to a final concentra- 
tion of 10 #g/ml. For each chase point, one 5-cm petri dish of semiconfluent 
HepG2  cells  was used.  Cells  were  pulsed with  [35S]methionine for the 
times indicated in the results, and incorporation of label was terminated by 
addition of nonradioactive methionine to a  final concentration of 1 raM. 
Where indicated, chloroquine (100 #M) was added at the beginning of the 
chase. Cells were lysed in lysis mix (see above) containing 10 #g of nonra- 
dioactive Tf per ml. The immunoprecipitations were performed following 
a  strict timetable, resulting in the final washed immunoprecipitate within 
4-5 h after lysis of the cells. However, prolonged incubation times during 
immunoprecipitation (up to 24 h) did not affect the amount of radiolabeled 
Tf coprecipitated with Tfr (data not shown). Tf from Tf-Tfr complexes was 
isolated by boiling the Staphylococcus aureus pellet in 20/zl 2 % (wt/vol) 
SDS for 5 min. NET buffer (950/A) was added, and the supernatant was 
precleared twice with normal rabbit serum and Staphylococcus aureus. Tf 
was then immunoprecipitated using the rabbit anti-human transferrin serum. 
Endo H digestions were performed as described (25). NANAse digestion 
on immunoprecipitates were performed as described (24). 
Tfr Binding to Immobilized Tf 
K562 cells were labeled with [3SS]methionine for 60 min, and used as a 
source of Tfr. Ceils were lysed using NP-40 lysis mix (pH 7.4). Debris was 
removed and the lysate was precleared with Sepharose. The lysate was in- 
cubated  with Tf-Sepharose (prepared  by coupling Tf to  CNBr-activated 
Sepharose) at 0°C (overnight) in the presence or absence of 10 t~g/ml com- 
peting Tf. After removal of  Tf-Sepharose, Tfr was immunoprecipitated from 
the unbound fraction with the mAb 66Ig10 (36). 
The Tf-Sepharose-bound material was washed three times with NET- 
buffer (pH 7.4) followed by three washes and a  1-h incubation (4°C) with 
buffer containing 50 mM NaAc (pH 5.1), 5 mM EDTA, and 150 mM NaC1. 
The elnted material was collected and Tfr was immunoprecipitated from it 
using 66Ig10 (36).  The Tf-Sepharose was subsequently washed with NET 
buffer (pH 7.4) and again Tfr was immunoprecipitated from the eluate. The 
immunoprecipitates were analyzed by SDS-PAGE under nonreducing con- 
ditions. 
Conversion of  apoTf during Secretion 
Two  dishes of semiconfluent HepG2  cells  were  labeled  with  125  #Ci 
[35S]methionine in methionine-free RPMI-1640 medium for 4  h in the ab- 
sence or presence of chloroquine (100 #M). To assess the possible role of 
free Fe  3+ in the medium, the identical experiment was performed includ- 
ing 10 t~M NaVO3 in the medium. K562 cells (4 x  107) were washed twice 
with PBS (0°C). Radiolabeled secretory proteins (containing Tf) obtained 
from HepG2 cells were added to the K562 cells and incubated for  1 h  at 
0°C. The K562 cells having bound Tf were washed twice with PBS (0°C), 
lysed in NP-40 lysis mix (pH 7.4) and Tfr was immunoprecipitated using 
the mAb 66Ig10 (36).  The unbound Tf was immunoprecipitated from the 
supernatant with the rabbit anti-human Tf serum. 
Results 
Secretion and Uptake of Glycoproteins by HepG2 
HepG2 cells synthesize and secrete considerable quantities 
of Tf (18). As in every rapidly dividing cell line, Tfr is also 
abundantly expressed.  In addition, HepG2 cells are positive 
for the asialoglycoprotein receptor (ASGR) (4,  10). Because 
many proteins are synthesized with N-linked glycans, these 
proteins  should be a  ligand  for the ASGR during  passage 
Figure 2. Tf and Tfr can be coimmunoprecipitated. (A) Coimmunoprecipitation of ligand and receptor. Radiolabeled  HepG2 supernatant 
was added to HepG2 cells at 0°C in DME or PBS. Nonbound proteins were removed,  the cells were washed and were subsequently  lysed 
at pH 5.1 or 7.4. Tfr was immunoprecipitated with the MAb 66Ig10 followed by a sequential  immunoprecipitation of free Tf with anti-Tf 
serum. The immunoprecipitates were analyzed by SDS-PAGE on a  10% gel.  Note the difference  in efficiency of coimmunoprecipitation 
of Tf with Tfr at pH 5.1 and 7.4 nrs; normal rabbit serum control. (B) Binding of Tf to Tfr during lysis.  HepG2 cells were labeled  with 
[35S]methionine for 15 min and chased for 60 min. To exclude that Tf binds to Tfr after lysis of the cells,  HepG2 cells were lysed in lysis 
mix containing different concentrations of nonradioactive Tf as indicated  above the figure. Tf-Tfr was immunoprecipitated with the mono- 
clonal antibody 66Ig10 and analyzed by SDS-PAGE on a  10%  gel. 
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minal galactose residue (10). Finally, apoE and the LDL 
receptor, both synthesized by HepG2 cells (34),  constitute 
a similar couple of receptor and corresponding ligand (13). 
To establish which of these ligand-receptor interactions 
can be visualized using metabolically labeled ligands, radio- 
labeled proteins secreted by HepG2 cells were offered to an 
unlabeled culture of HepG2 cells. At different time points, 
samples of these cultures were taken, and analyzed by SDS- 
PAGE for the proteins retained from the mixture of radioac- 
tive proteins offered. Surprisingly, the pattern of polypep- 
tides detected was remarkably simple (Fig. 1), and could be 
explained by the presence of Tf, albumin, and apoE, as de- 
termined by immunoprecipitation with the relevant antisera 
(data not shown). Albumin sticks nonspecifically to mem- 
branes (28).  Indeed, the extent of albumin binding did not 
show any systematic variation with time or temperature (data 
not shown).  The kinetics of uptake of Tf and apoE were 
widely different: a  continuous increase in the amount of 
apoE was observed until 120 min, whereas the uptake of Tf 
had reached a plateau already after 15 min. These observa- 
tions  are  consistent with  internalization of apoE  via the 
LDL-receptor (13), and Tf entering the "If cycle (6, 16, 17). 
Because of the rapid cycling time of Tfr (8-15  min) (6),  a 
steady-state distribution of radiolabeled Tf over the intra- 
and extracellular compartments is rapidly attained. 
Prior  exposure  of  radiolabeled  proteins  secreted  by 
HepG2 to neuraminidase (NANAse) abolished almost com- 
pletely uptake of apoE, but not binding of albumin or uptake 
of Tf.  Contrary to expectation,  no increase in uptake or 
binding of major desialylated glycoproteins to ASGR was 
observed. Whether the two clones of HepG2 cells (obtained 
from different investigators) both express only low levels of 
ASGR,  or  whether the  native,  NANAse-treated,  HepG2 
secretory proteins are inferior substrates for the ASGR re- 
mains to be established. Efficacy of NANAse treatment was 
checked by  1D-IEF  analysis of Tf and al-antitrypsin (a~- 
AT) (data not shown), and can also be assessed from the 
difference in  the  relative  molecular  mass  for  NANAse- 
exposed  and control  Tf (Fig.  1).  For the  remainder,  we 
focussed our attention on the Tf-Tfr couple, because of the 
high levels expressed by HepG2 and of the availability of re- 
agents recognizing Tf and Tfr. 
Removal of sialic acids in no way interfered with uptake 
of Tf (29).  Moreover, Tf produced by cells in the presence 
of the mannosidase inhibitors 1-deoxynojirimycin (dMM) or 
swainsonine (11) was likewise taken up efficiently (data not 
shown).  We conclude that the type of N-linked carbohy- 
drates carried by Tf is not a factor that determines its ability 
to bind to Tfr. This point is of relevance to our biosynthetic 
experiments described below. 
lmmunoprecipitation of the Tf- Tfr Complex 
We established the conditions for the recovery of Tf-Tfr 
complexes  by  immunoprecipitation  at  two  different pH 
values.  At neutral pH,  only the Tf-Tfr complex is stable, 
whereas at acidic pH (pH <5) the Tf in the Tf-Tfr complex 
is converted to apoTf.  The apoTf-Tfr  complex is stable at 
acidic pH (7,  17). In the course of the normal Tf cycle, the 
Tf-Tfr complex reaches the acidic compartment where Fe  3÷ 
is  released from Tf,  resulting in the  conversion of Tf to 
apo'lY. As long as the receptor-ligand complex is in acom- 
partment of low pH it is stable: upon return to the cell sur- 
face,  and thus exposure  to neutral pH,  apoqY dissociates 
from Tfr (7,  17). 
HepG2 cells were exposed to 35S-labeled Tf-containing 
protein mixture (labeled HepG2 supernatant) in PBS (con- 
taining no Fe  3÷) or DME  (containing Fe3÷). Lysates were 
prepared at pH 5.1 (where Tf-Tfr is converted to apoTf-Tfr, 
which is stable at pH 5.1) and at pH 7.4, where only Tf-Tfr 
is stable.  The anti-Tfr antibody 66Ig10  (36)  recovers Tfr- 
bound Tf under all experimental conditions tested.  Cells 
maintained  in  DME  invariably  give  higher  recovery  of 
bound Tf, presumably because compared to cells maintained 
in PBS a smaller proportion of the available Tf is in the apo 
form, which is unable to bind to Tfr at neutral pH (Fig. 2 A). 
A second round of immunoprecipitation with a polyclonal 
rabbit anti-human Tf antiserum yields free Tf not in a com- 
plex with Tfr. This fraction is greater when lysis is carried 
out at pH 5.1. The small amount of Tf isolated in the second 
round of immunoprecipitation at neutral pH could represent 
"IT bound to molecules other than Tfr or molecules derived 
from Tf-Tfr complexes disrupted in the course of  lysis. Thus, 
immunoprecipitation  at pH 5.1 and at pH 7.4 allows the isola- 
tion of ligand-receptor complexes, but the stability of this 
complex is lower at pH 5.1. 
Because lysates of biosynthetically  labeled HepG2 contain 
both Tfr and free "If, precautions must be taken to prevent 
association of free radiolabeled "If with Tfr.  For example, 
this situation could arise when radiolabeled Tf present in the 
ER could combine after lysis with Tfr present in a different 
subcellular compartment. To establish whether this possibil- 
ity indeed applies, HepG2 cells were pulse labeled for 15 
min and chased for 60 min. Immunoprecipitation of Tfr was 
then carried out in the presence of increasing amounts of 
competing nonradioactive Tf. The amount of Tf complexed 
with Tfr was reduced by the inclusion of 10/zg/ml of nonra- 
diolabeled "If, suggesting that some association of receptor 
and ligand did indeed take place in the lysate (Fig. 2 B). 
Raising the concentration of competitor Tf to 100/~g/ml did 
not  further  reduce  the  amount of radiolabeled  Tf coim- 
munoprecipitated. We therefore routinely included 10/~g/ml 
of competing Tf in our lysis mix in subsequent experiments. 
Tf- Tfr Interaction During Biosynthesis 
To investigate the interaction of Tf and Tfr in the course of 
biosynthesis, a series of pulse-chase experiments was car- 
ried out (Fig. 3).  Analysis of the immunoprecipitates pre- 
pared at pH 7.4 with the anti-Tfr mAb 66Ig10  show rapid 
transport of Tfr to the trans-Golgi apparatus within 30 min 
after synthesis, when Tfr becomes resistant to Endo H diges- 
tion (Fig. 3 A). Mature Tfr contains two complex and one 
high-mannose carbohydrate chain and is therefore always 
partially susceptible to Endo H treatment (27, 31). After a 
15-rain chase, labeled Tf is coimmunoprecipitated with Tfr. 
The identity of Tf was proven by dissociation of the anti-Tfr 
immunoprecipitates, followed by a reprecipitation with the 
rabbit anti-human "If serum (Fig. 3 B). In the Tfr-bound Tf 
fraction, no modification to complex-type N-linked glycans 
is seen.  Analysis of the remaining free Tf present in the 
lysates shows the appearance in time of Tf of a higher appar- 
ent molecular weight, comigrating with Tf recovered from 
the  supernate  (Fig.  3 B).  This Tf contains complex-type 
N-linked glycans only. Note that the amount of Tfr recovered 
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analysis of the Tf association with Tfr. HepG2 cells were labeled 
with [35S]methionine for 15 min and chased for the times indicated 
above gel.  (LEO) Tfr is immunoprecipitated  from the lysates and 
analyzed by SDS-PAGE on a 10% gel. Tfr shift to a higher apparent 
molecular weight at 15 min of chase. From 15 min of chase Tfcan 
be immunoprecipitated with Tfr. The amount of  Tf  immunoprecipi- 
tated with Tfr increases up to 60 min and decreases after 120 min 
of chase. The position of Tf and Tfr are indicated. The identity of 
Tf was proven by dissociation  of the Tf-Tfr complex followed by 
isolation of "IT by immunoprecipitation  (see B).  (Right) The im- 
munoprecipitates  shown in the left panel were digested with Endo 
H. The Tf isolated with the Tfr complex is fully Endo H sensitive 
and therefore intracellular. Mature Tfr contains one high-mannose 
and two complex-type carbohydrate chains and therefore remains 
partially sensitive for Endo H. (B, left) Tfr-bound Tf. The Tfr im- 
munoprecipitates  as shown in A (leO) were denatured,  and Tf was 
immunoprecipitated  with a rabbit anti-human Tf serum. The mi- 
gration of Tfr-bound Tf is compared with that of secreted Tf. Tfr- 
bound Tf migrates faster than secreted Tf. (Right) Analysis of free 
intracellular  Tf. Remaining free Tf was immunoprecipitated  from 
the lysates after the first round of immunoprecipitation of Tfr. Most 
newly synthesized Tf do not bind to Tfr (compare with A). Note 
the conversion of Tf to a higher apparent molecular weight after 30 
min of chase that is not visible with Tf  recovered in the Tfr-Tf  com- 
plex. (C) Secretion of Tf. Tf was immunoprecipitated  from the su- 
pernatants  of pulse-labeled  HepG2 cells.  Secretion of Tf starts at 
'~60 min of chase. (D) Analysis of Tf and Tfr on ID-IEE The im- 
munoprecipitated Tf-Tfr complex (see A, left) and Tf isolated from 
the immunoprecipitated "Pf-Tfr  complex (see also B, left) were ana- 
lyzed on 1D-IEE The position of Tf and Tfr are indicated. Sialyla- 
tion of Tfr (indicating arrival in the trans-Golgi apparatus) results 
in a shift to a more acidic position on 1D-IEF and is visible after 
15 min of chase. Hardly any sialylation of Tf bound to Tfr is ob- 
served (see also Fig. 4 A). Cathode  is at the top. 
by the mAb 66Ig10 increases towards the later time points 
of chase. The 66Ig10 antibody was raised against intact cells, 
and thus presumably dimeric receptor. It is possible that the 
affinity of 66Ig10 is higher towards the dimeric forms of Tfr. 
The immunoprecipitates shown in Fig.  3, A and B  were 
also analyzed by  1D-IEF to allow the  detection  of charge 
modifications of Tf and Tfr. Already after 15 min of chase, 
Tfr arrives in the trans-Golgi  apparatus as monitored by a 
shift on 1D-IEE due to the addition of (negatively charged) 
sialic acids (Fig. 3 D) (3, 30). This modification is essentially 
complete after 60 min of chase. No such modification is seen 
for Tf,  in agreement with the results of Fig.  3, A and B. 
The amount of Tf recovered in the anti-Tfr immunopre- 
cipitates prepared at pH 7.4 increases from 15 until 120 min 
of chase and  subsequently  decreases  (Fig.  3  A).  This de- 
crease represents loss of Tf from the Tf-Tfr complex due to 
events described below. Tf bound to Tfr is fully Endo H sen- 
sitive (Fig. 3 A), showing that binding of Tf to Tfr does take 
place intracellularly.  Secreted "IT is Endo H  resistant (data 
not shown) and fully sialylated (Fig. 4 A). The early binding 
of Tf (at  15 min of chase) at which no secretion of Tf can 
be detected (Fig. 3 C), is further proof that this interaction 
takes place intracellularly. 
The data shown thus far establish that Tf can interact with 
Tfr during biosynthesis,  and that the bound  Tf is released 
subsequently from the Tf-Tfr complex. Where does this dis- 
sociation take place? q"f is converted to apoTf in subcellular 
compartments with a pH lower than 5.5 (7, 17). In principle, 
this could occur in (parts of) the TGR; its resident pH is not 
easily established, but is known to be slightly acidic (2, 14). 
If Tf were converted to apoTf in the TGR, then the Tf-Tfr 
complex likewise will be converted there to apoTf-Tfr, and 
dissociate upon arrival at the cell surface. Otherwise, it is the 
Tf-Tfr complex that will arrive at the cell surface, which may 
then enter the  usual  Tf cycle.  Another explanation is that 
there is a direct transfer of the Tf-Tfr complex produced bio- 
synthetically to an intracellular compartment that is part of 
the endocytic pathway. This would also result in delivery of 
Tf-Tfr complex to an acidic compartment. 
To show that an acidic compartment is involved in the dis- 
sociation of the biosynthetically labeled Tf-Tfr complex, a 
pulse-chase  experiment was performed in  the  absence or 
presence of 100/~M chloroquine, a compound that neutral- 
izes acidic compartments. Cells were lysed in a buffer of pH 
7.4  or  5.1. Immunoprecipitation at  pH  7.4  results  in  the 
recovery of the Tf-Tfr complex only, whereas immunopre- 
cipitation at pH 5.1  results in the conversion of Tf-Tfr and 
the recovery of all complexes in the apoTf-Tfr form. To im- 
prove the signal-to-noise ratio, the isolated Tf-Tfr complex 
was dissociated by SDS treatment, and "If was immunopre- 
cipitated at pH 7.4. The immunoprecipitates were analyzed 
by 1D-IEF to visualize the sialylated forms of'If: they repre- 
sent mature Tf. (Tf contains two complex N-linked glycans 
[37] with one to four sialic acids; an average of two to three 
sialic acids per glycan [Fig. 4 B].) Neutralization of acidic 
compartments with  chloroquine  results  in  a  considerably 
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after passage of an acidic compartment. (A) 
Stability  of Tf-Tfr and  apoTf-Tfr  through 
passage of an acidic compartment. HepG2 
cells were labeled  with [35S]methionine for 
15 rain and chased for the times indicated. 
Where indicated  chloroquine was added at 
the beginning of  the chase. The Tfr-Tf  com- 
plex was immunoprecipitated with the anti- 
Tfr mAb 66Ig10 from equal amounts of TCA 
radioactivity in lysates at pH 7.4 (top) or 5.1 
(bottom). The immune complexes were dis- 
sociated by exposure to SDS at 95°C and Tf 
derived from the Tfr-Tf complex was im- 
munoprecipitated and analyzed by 1D-IEE 
To show the position of sialylated  and non- 
sialylated  Tf, labeled  Tf isolated  from the 
medium was analyzed in parallel  before or 
after digestion  with NANAse. The position 
of sialylated Tfis indicated by brackets.  The 
presence of sialylated Tf indicates passage of 
Tf  through the trans-Golgi complex. Clearly, 
more sialylated  Tf-Tfr is  recovered  when 
acidic compartments are neutralized.  How- 
ever, the amounts of Tf-Tfr including  apo- 
Tf-Tfr recovered (at pH 5.1) are comparable 
upon chloroquine treatment.  Cathode is at 
the top.  (B) Tf is not converted to apoTf in 
the  TGR.  HepG2 cells  were  labeled  with 
[35S]methionine for 3 h in the presence or 
absence of 100/~M chloroquine.  A separate 
experiment was performed  including NaVO3 
in the  medium because VO3- precipitates 
Fe  3+ cations. K562 cells were then incubated 
with the radiolabeled  HepG2 supernatant at 
0°C for 1 h, the nonbound fraction was re- 
moved, and the Tfr-Tf complex was immu- 
noprecipitated  from K562  lysates.  Tf was 
immunoprecipitated from the nonbound frac- 
tion. Immunoprecipitates were analyzed by 
SDS-PAGE on 10%  gel. 
higher recovery of sialylated Tf bound to Tfr when isolated 
at pH 7.4 (Fig. 4 A, top). Thus an acidic compartment is in- 
volved in the dissociation of Tf from Tfr. 
To establish whether the release of Tf from Tfr is preceded 
by conversion of Tf-Tfr to apoTf-Tfr, we isolated Tfr at pH 
5.1.  At pH 5.1,  the apoTf-Tfr complex is recovered. In con- 
trast to lysis at pH 7.4, lysis at pH 5.1 showed a considerable 
recovery of sialylated (apo)Tf bound to Tfr (Fig. 4 A,  bot- 
tom) in comparable quantities for control- and chloroquine- 
treated cells. The Tf complexed to Tfr and isolated at pH 5.1 
but not at pH 7.4 must therefore be apoTf.  Tf bound to Tfr 
in cells exposed to chloroquine will ultimately  be released 
from Tfr by competition with Tf present in the medium (17). 
That conversion of Tf to apoTf does not take place in the 
secretory pathway (TGR) is based on the following experi- 
ment.  Binding  of Tf to  Tfr  on  the  cell  surface  of intact 
erythroleukemic K562 cells was used to assess the relative 
amounts of secreted Tf and apoTf from control and chloro- 
quine-treated cells. Inclusion of choloroquine in the HepG2- 
labeling medium did not produce a shift in the amount of Tf 
bound to K562 cells relative to the unbound fraction, which 
must  include  apoTf.  Inclusion  of  VO3-  in  the  labeling 
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result: under the latter conditions, conversion of apoTf to Tf 
in the medium is precluded (Fig.  4  B).  Had conversion of 
Tf to apoTf occurred in the secretory pathway in untreated 
HepG2  cells,  no  Tfr-bound  material  would have been ex- 
pected. However, binding of Tf to the K562 Tfr is observed, 
and thus we conclude that the TGR is not sufficiently acidic 
to allow the conversion Tf to apoTf. 
Tf-Tfr Interactions Early During Biosynthesis 
At early time points of chase, no Tf bound to Tfr is detectable 
(Figs.  3 A and 5 A). Because at that time both Tf and most 
Tfr will be located in the ER (since both are fully Endo H 
sensitive, Fig. 3 A), the ER-resident Tfr apparently does not 
immediately acquire ligand binding capacity, apoTf will not 
bind to Tfr at neutral pH. After 15 min of chase, Tf binding 
becomes detectable (Fig.  3 A). To provide higher temporal 
resolution  in the analysis  of events  leading  to a  functional 
Tfr, HepG2 cells were pulsed for 5  min and chased for the 
times indicated (Fig. 5 A). Tfr was analyzed under reducing 
and nonreducing conditions,  the latter allowing the separa- 
tion  of  the  Tfr  monomer  and  the  disulfide  linked  Tfr 
homodimer (Fig. 5 A). "IT binding was detected at 20 min of 
chase, consistent with the earlier experiment (Fig. 3 A). The 
inability  to observe interactions  of Tfr with Tf during  the 
earliest time points of chase is not a consequence of incom- 
plete N-linked glycan maturation:  pulse-chase experiments 
in the presence or absence of the glucosidase inhibitors (11) 
dNM or castanospermine revealed no effect on Tf-Tfr inter- 
actions (data not shown).  The acquisition of "If binding ca- 
pacity coincided with covalent Tfr dimerization (Fig.  5 A). 
Formally, these results do not allow the conclusion that only 
the disulfide linked Tfr dimer has Tf binding capacity (since 
radiolabeled  Tf can bind to nonradioactive Tfr synthesized 
during the chase) and, therefore,  that the interaction of Tfr 
with Tf can in fact occur in the ER. 
To show that Tf-Tfr interactions can take place in the ER, 
pulse-labeled HepG2 cells were incubated at 10°C for differ- 
ent periods  (Fig.  5 B).  When analyzed under nonreducing 
conditions, the relative amount of covalently dimerized Tfr 
was found to increase with time, and, in parallel,  the quan- 
tity of Tf bound.  Even though membrane traffic is arrested 
Figure 5. Interactions of Tf and 
Tfr early during biosynthesis. 
(A)  Formation  of disulfide- 
linked Tfr dimer early during 
biosynthesis. HepG2 cells were 
labeled  for 5 min and chased 
for the times indicated. Tfr was 
immunoprecipitated and ana- 
lyzed by SDS-PAGE under re- 
ducing and nonreducing con- 
ditions.  The  disulfide-linked 
Tfr homodimer (2  ×  Tfr) is 
observed  under  nonreducing 
conditions  after  20  min  of 
chase.  Tf binding is observed 
as  soon  as  the  covalent  Tfr 
dimer has been formed. The 
positions of the  covalent  Tfr 
dimer  (2  x  Tfr), Tfr mono- 
mer, and Tf are indicated.  (B) 
Time dependency of  Tf-Tfr in- 
teractions.  HepG2 cells  were 
labeled for 7.5 min and chased 
at  10°C  for  the  times  indi- 
cated. At 10°C all intracellu- 
lar transport is inhibited as in- 
dicated by the absence of any 
further posttranslational  modi- 
fications (see Fig. 3). Tfr was 
immunoprecipitated  out  of 
equal amounts of TCA-precip- 
itable  radioactivity,  followed 
by a sequential  immunoprecipitation of ot~AT. Immunoprecipitated Tfr was analyzed under reducing and nonreducing conditions.  Disul- 
fide-linked  Tfr dimers (2 x  Tfr) as well as Tfr-bound Tf are observed after 1 h of chase at  10°C. (C) Disulfide-linked  Tfr dimer but not 
the Tfr monomer has Tf binding capacity.  A lysate (pH 7.4) of the erythroleukemic cell line K562 (labeled  with [35S]methionine) was in- 
cubated with Tf-Sepharose in the absence (lane marked -) or presence (lane marked 4- Tf) of 10/~g/ml Tfas indicated.  Tfr was immunopre- 
cipitated from the unbound fraction and analyzed by SDS-PAGE under nonreducing conditions (lanes marked -,  4- Tf, pH 7). The positions 
of Tfr monomer and the disulfide  linked  Tfr dimer (2 x  Tfr) are indicated.  Lanes 3-5 Tfr recovered from the unbound fraction. The Tf- 
Sepharose-bound fraction was exposed to pH 5.1, resulting  in the formation of apoTf-Tfr complexes.  Tfr was not eluted by this procedure 
(lane pH 5). The Tf-Sepharose-bound fraction was then again exposed to pH 7.4 (rightmost lane, pH 7). Tfr was now recovered from 
the eluate.  The disulfide-linked  Tfr homodimer is released  because the apoTf-Tfr complex is not stable at pH 7.4. Note the minor fraction 
of Tfr monomer released. 
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either Tf, Tfr, or t~IAT as deduced from characteristic shift 
in electrophoretic mobility), covalent Tfr dimerization pro- 
ceeds at  10°C, and results in the generation of a functional 
Tfr. We conclude that this Tfr interacts with Tf in the ER. 
To show directly that it is the covalent Tfr homodimer that 
binds Tf, a lysate ofK562 cells (which express large amounts 
of Tfr)  that  had  been labeled  with  [3sS]methionine  for 60 
min, was passed over a Tf-Sepharose column. Tfr was immu- 
noprecipitated from the flow-through of this column and ana- 
lyzed by nonreducing SDS-PAGE (Fig. 5 C). The disulfide- 
linked  Tfr homodimer was found to bind to Tf-Sepharose 
and could or.ly be maintained in the flow-through when the 
lysate was supplemented  by excess,  free Tf before passage 
over  Tf-Sepharose.  Elution  of the  Tf-Sepharose-retained 
material at pH 5.1 did not result in the release of Tfr. At pH 
5.1  Tf  is  converted  to  apoTf  (Fe  3+  is  released)  but  the 
apoTf-Tfr complex  dissociates  only  when  exposed  subse- 
quently to neutral pH (7,  17). Indeed, subsequent exposure 
of the pH 5.1-treated,  bound fraction to pH 7.4 resulted in 
the release of the disulfide-linked Tfr homodimer. Only a mi- 
nor  fraction  of Tfr  monomer  (or  nondisulfide-linked  Tfr 
dimer;  these two cannot be distinguished by this criterion) 
was observed (Fig.  5  C,  last lane). 
Discussion 
The intracellular  interactions of Tf and Tfr synthesized by 
the  human  hepatoma  cell  line  HepG2  that  we  have 
documented, are depicted schematically in Fig. 6. Early dur- 
ing biosynthesis the Tfr monomer is converted to a disulfide- 
linked  homodimer  (Fig.  5  A).  Covalent  dimerization  can 
proceed even at  10°C, albeit slowly, in the ER (Fig.  5 B). 
The process of covalent dimerization is largely completed in 
the ER (Fig. 5, A and B), but in any case, before arrival in 
the trans-Golgi  apparatus.  The formation of this disulfide- 
linked Tfr may proceed through a nondisulphide-linked Tfr 
dimer intermediate.  The small quantity of Tfr monomer re- 
covered in the experiment shown in Fig. 5 C may in fact de- 
rive from such noncovalent dimers.  Tfr obtains Tf binding 
capacity upon dimerization  (Fig.  5  C).  The  formation  of 
disulfide-linked Tfr dimers is not a prerequisite for transport 
out  of the  ER  because  elimination  of the  two  interchain 
disulfide bridges by site-directed mutagenesis does not elim- 
inate surface expression or Tf binding properties of Tfr (15). 
However, it is possible that Tfr monomers do not leave the 
ER and Tfr can only do so through the formation of (covalent 
or noncovalent) dimers (see also reference  12). 
The Tf in the Tf-Tfr complex must contain Fe  3+, which it 
Oo 
OQOo 
I  Tfr  monomer 
II  Tfr  dlmer  (noncovalentl 
III  Tfr-dimer  (covalent) 
IV  Apo-Tf  -) Tf 
V  transport  through  Golgi 
glycan  modifications 
Vi  externalization  Tfr-Tf,Tf  and  apo-Tf 
VII  internalization  of  Tfr-Tf and  Tfr 
VIII  conversion  Tf-)apo-Tf  on Tfr 
IX  recycling  Tfr  and  Tfr-apo-Tf 
X  release  apo-Tf  from Tfr-apo-Tf 
Figure 6. Schematic  representation  of the Tf and 
Tfr interactions  in HepG2 cells.  The Tfr mono- 
mer,  as  initially  synthesized,  is  converted to  a 
disulfide-linked  Tfr dimer.  This may go through a 
nondisulfide  linked Tfr dimer as an intermediate. 
The Tfr dimer has Tf binding activity  in the ER, 
whereas the Tfr monomer has not. The resulting 
Tf-Tfr complex is transported through the Golgi 
apparatus and the TGR. The TGR has a pH >5.5. 
Direct transfer  of Tf-Tfr and Tfr from the secre- 
tory pathway (trans-Golgi) to the endocytic route 
(from IV to VIII) is a possibility  not excluded by 
our experiments.  When the Tf-Tfr complex arrives 
at the cell surface, the Tf-Tfr is internalized and ar- 
rives in an (acidic) endosome where Tf releases its 
Fe  3+ and is converted to apoTf. The apoTf-Tfr com- 
plex (stable at acidic pH) recycles back to the cell 
surface. The apoTf-Tfr complex is unstable at neu- 
tral pH, dissociates,  and Tfr can bind a new Tf 
molecule from the surrounding medium and starts 
a new Tf cycle. 
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Tfr, because Tf is synthesized in molar excess (Fig. 3 B; Tf 
contains 9  [21, 37], Tfr contains 11 methionines [23, 32]). 
In addition,  not all newly synthesized Tf may have bound 
Fe  3÷ and thus be able to bind to Tfr. The Tf-Tfr complex is 
transported through the Golgi and the trans-Golgi reticulum 
(TGR). The pH in the TGR is not sufficiently acidic to con- 
vert free Tf to apoTf (Fig. 4 B) and must therefore be higher 
than pH 5.5  (7,  17) (unless the residence time of Tf in the 
TGR would be in the order of 1.5 min, the reported half-time 
of conversion ofTfto apoTf at pH 5 [7]). Thus, the local con- 
ditions are probably compatible with safe passage of Tf-Tfr 
through the TGR. 
The experiments in Fig.  4  show that the Tf-Tfr complex 
is rapidly delivered from the TGR to a compartment of low 
pH, the target of action of chloroquine. The exact route by 
which this acidic compartment is reached cannot be estab- 
lished with certainty from our experimental data. It is possi- 
ble that the Tf-Tfr complex is deposited at the cell surface, 
from which it is rapidly internalized via the usual endocytic 
pathway (7,  17).  Alternatively,  the Tf-Tfr complex may be 
delivered  directly  to the endocytic pathway,  and enter the 
transferrin cycle intracellularly. The kinetics of this process 
as observed experimentally are too rapid to allow a clear dis- 
tinction between these two possibilities.  For molecules like 
the mannose-6-phosphate receptor (19) and the major histo- 
compatibility complex class  II antigens (26),  a direct con- 
nection between the TGR and the endocytic route has been 
shown. 
Because  Tfr  and  Tf  can  interact  intracellularly  in  the 
course of biosynthesis, this possibility probably also exists 
for other ligand-receptor combinations synthesized by one 
and the same cell. In the case of a growth factor and its recep- 
tor, such interactions can result in transport to the cell sur- 
face and delivery of a growth signal. Whether a growth sig- 
nal can already be delivered after binding of a growth factor 
to its receptor in the ER or Golgi is not known. There are 
several  ways by  which premature  interaction of receptors 
with their ligands could be prevented. For example, covalent 
modifications (e.g., disulfide bonding, glycan modifications, 
phosphorylations) required for full ligand binding potential 
may take place at a time and location where ligand and recep- 
tor are no longer available in the same compartment.  The 
presence of cofactors (e.g., divalent cations, optimal pH for 
binding) may likewise be a controlling factor. 
Coexpression of EGF or TGFct and the EGF-receptor has 
been observed in a number of tumors and cell lines (8) and 
a similar situation may apply to other growth factor-growth 
factor  receptor  combinations.  Their  intracellular  interac- 
tions,  which could ultimately contribute to tumor growth, 
might  go  along  lines  parallel  to  those  outlined  here  for 
Tf-Tfr. 
We thank Dr. J. Hilkens for providing us with generous quantities of the 
66Ig10 MoAb, Yvonne Schaap-da Silva de Freitas, and Drs. J. Bolscher 
and T.  Schumacher for critically  reading the manuscript, and we thank 
Paulien Sobels for preparation of the manuscript. 
This research was supported by the Queen Wilhelmina Fund (KWF) 
grant 85-10. 
Received  for publication 23  February 1990 and in revised form 28  May 
1990. 
References 
1. Alvarez,  E., N. Girones,  and R. J. Davis.  1989. Intermolecular disulfide 
bonds are not required for the expression of the dimeric state and func- 
tional activity of  the transferrin receptor. EMBO (Eur. Mol. Biol. Organ.) 
J.  8:2231-2240. 
2. Anderson,  R. G. W., and R. K. Pathak.  1985. Vesicles and cistemae  in 
the trans-Golgi  apparatus  of human vesicles are acidic compartments. 
Cell. 40:635-643. 
3. Berger,  E.  G., M.  Turnher,  and U. Muller.  1987. Galactosyltransferase 
and sialyltransferase are located in different subcellular compartments in 
HELA cells.  Exp. Cell Res.  173:267-273. 
4. Bischoff, J., S. Libresco, M. A. Shia, and H. F. Lodish.  1988. The H1 and 
H2 polypeptides associate to form the asialoglycoprotein receptor in hu- 
man hepatoma cells. J.  Cell Biol. 106:1067-1074. 
5. Carpenter, G. 1987. Receptors for epidermal growth factor and other poly- 
peptide mitogens. Annu.  Rev.  Biochem.  56:881-914. 
6. Ciechanover,  A., A. L.  Schwartz, A.  Dautry-Varsat,  and H. F. Lodish. 
1983. Kinetics of internalization of transferrin and the transferrin  recep- 
tor in a human hepatoma cell line.  Effect of lysosomotropic  agents. J. 
Biol.  Chem. 258:9681-9689. 
7. Dautry-Varsat,  A., A. Ciechanover,  and H. F. Lodish.  1983. pH and the 
recycling  of transferrin  during  receptor-mediated  endocytosis.  Proc. 
Natl. Acad.  Sci. USA. 80:2258-2262. 
8. Di Marco, E., J. H. Pierce, T. P. Flemming, M. H. Kraus, C. J. Molloy, 
S. A. Aaronson,  and P.  P.  Di Fiore.  1989. Autocrine  interactions be- 
tween TGFa and the EGF receptor: quantitative requirements for induc- 
tion of the malignant phenotype.  Oncogene. 4:831-838. 
9.  Dobberstein,  B., H. Garoff, G. Warren,  and P. J. Robinson.  1979. Cell- 
free synthesis and membrane insertion of mouse H-2D  ° histocompatibil- 
ity antigen and/~2-microglobulin.  Cell. 17:759-769. 
10. Drickamer,  K. 1988. Two distinct classes of carbohydrate-recognition  do- 
mains in animal lectins. J.  Biol. Chem. 263:9557-9560. 
11.  Fuhrmann,  U., E. Bause, and H. L. Ploegb.  1985. Inhibitors of oligosac- 
charide processing.  Biochem. Biophys.  Acta. 825:95-100. 
12. Gething,  M.-J., K. McCammon,  and J.  Sambrook.  1986. Expression of 
wild-type and mutant forms of influenza hemagglutinin: the role of fold- 
ing in intracellular  transport.  Cell. 46:939-950. 
13. Goldstein, J.  L., M. S. Brown, R. G. W. Anderson,  D. W. Russell, and 
W. J. Schneider.  1985. Receptor-mediated endocytosis: concepts emerg- 
ing from the LDL-receptor.  Annu. Rev. Cell Biol. 1:1-39. 
14.  Hopkins,  C.  R.  1983. Intracellular  routing  of transferrin  and transferrin 
receptors  in epidermal  carcinoma A431 cells.  Cell. 35:321-330. 
15. Jing,  S., and I. S. Trowbridge.  1987. Identification of the intermolecular 
disulfide bonds of the human transferrin receptor and its lipid-attachment 
site. EMBO  (Eur. Mol. Biol. Organ.) J.  6:327-331. 
16. Karin, M., and B. Mintz. 1981. Receptor-mediated endocytosis of transfer- 
rin in developmentally totipotent mouse teratocarcinoma  stem cells. J. 
Biol.  Chem. 256:3245-3252. 
17.  Klausner,  R.  D.,  J.  van  Renswoude,  G.  Ashwell,  C.  Kempf,  A.  N. 
Schechter,  A.  Dean,  and K. R.  Bridges.  1983. Receptor-mediated  en- 
docytosis of transferrin  in K562 cells. J.  Biol. Chem. 258:4715-4724. 
18. Knowles, B. B., C. C. Howe, and D. P. Aden. 1980. Human hepatocellular 
carcinoma cell lines secrete the major plasma proteins and hepatitis B sur- 
face antigen.  Science  (Wash. DC). 209:497--499. 
19. Kornfeld,  S.  1987. Trafficking of lysosomal enzymes. FASEB (Fed. Am. 
Soc. Exp. Biol.)J.  1:462-468. 
20.  Lozzio, C. B., and B. B. Lozzio. 1975. Human chronic myelogenous leuke- 
mia cell-line  with positive  philadelphia  chromosome.  Blood. 45:321- 
334. 
21.  MacGillivray,  R.  T.  A.,  E.  Mendez,  J.  G.  Shewale,  S.  K.  Sinha,  J. 
Lineback-Zins, and K. Brew.  1983. The primary structure of human se- 
rum transferrin.  J.  Biol. Chem. 258:3543-3553. 
22.  Mahley, R. W.  1988. Apolipoprotein E: cholesterol transport protein with 
expanding role in cell biology.  Science  (Wash. DC). 240:622-630. 
23.  McClelland, J., L. C. Kuhn, and F. H. Ruddle. 1984. The human transfer- 
fin receptor gene: genomic organization and the complete primary struc- 
ture of the receptor deduced from a cDNA sequence. Cell. 39:267-274. 
24.  Neefjes, J. J., B. S. Brear-Vriesendorp,  G. A. van Seventer, P. Ivanyi, and 
H. L.  Ploegh.  1986. An improved biochemical method for the analysis 
of HLA class I antigens. Definition of new HLA class I subtypes. Hum. 
Immunol.  16:169-181. 
25.  Neefjes,  J. J., J.  M.  H.  Verkerk,  H.  J.  G.  Broxterman,  G.  A.  van der 
Marel, J. H. van Boom, and H. L. Ploegh. 1988. Recycling glycoproteins 
do not return  to the cis-Golgi. J.  Cell Biol. 107:79-87. 
26.  Neefjes, J. J., V. Stollorz,  P. J.  Peters,  H. J.  Geuze,  and H. L. Ploegh. 
1990. The biosynthetic pathway of MHC Class H but not of Class I mole- 
cules intersects with the endocytic route.  Cell. 61:171-183. 
27. Omary,  M.  B., and I.  S.  Trowbridge.  1981. Biosynthesis of the human 
transferrin receptor in cultured cells. J. Biol. Chem. 256:12888-12892. 
28.  Reed, R. G., and C. M. Burrington.  1989. The albumin receptor effect may 
be due to a surface-induced conformational change in albumin. J. Biol. 
Chem. 264:9867-9872. 
29.  Regoeczi,  E.,  P.  A.  Chindemi,  M.  T.  Debanne,  and P.  A.  Charlwood. 
Neefjes et al. Ligand-Receptor  Interactions During Biosynthesis  1391 1982. Partial resialylation of human  asialotransferrin type 3 in the rat. 
Proc.  Natl.  Acad.  Sci.  USA.  79:2226-2230. 
30.  Roth,  J.,  D.  J.  Taatjes,  J.  M.  Lucocq,  J.  Weinstein, and J.  C.  Paulson. 
1985.  Demonstration of an extensive trans-tubular network continuous 
with the Golgi apparatus  stack that may function  in glycosylation. Cell. 
43:287-295. 
31.  Schneider,  C., R. Sutherland,  R. Newman,  and M. Greaves.  1982. Struc- 
tural features of the cell surface receptor for transferrin that is recognized 
by the monoclonal  antibody  OKT9.  J.  Biol.  Chem.  257:8516-8522. 
32.  Schneider,  C., M. J. Owen, D.  Banville, and J.  G. Williams. 1984. Pri- 
mary structure  of human transferrin receptor deduced from a mRNA se- 
quence.  Nature  (Lond. ).  311:675-678. 
33.  Smith,  K.  A.  1988.  Interleukin-2:  inception,  impact,  and  implications. 
Science  (Wash.  DC).  240:1169-1179. 
34.  Thrift, R. N., T. M. Forte, B. E. Cahoon,  and V. G. Shore.  1986. Charac- 
terization of lipoproteins produced by the human liver cell line HepG2, 
under defined conditions.  J.  Lipid Res.  27:236-250. 
35.  Turkewitz, A.  P.,  A.  L.  Schwartz,  and S.  C.  Harrison.  1988.  A  pH- 
dependent  reversible conformational  transition of the human transferrin 
receptor leads to self-association.  J.  Biol.  Chem.  263:16309-16315. 
36.  Van de Rijn, M., A. H. H. Geurts van Kessel, V. Kroezen,  A. J. van Ag- 
thoven,  K.  Verstijnen,  C. Terhorst, and J.  Hilgers. 1983.  l.x~alisation 
of a gene controlling the expression of the human transferrin receptor to 
the region ql2-qter of chromosome 3.  Cytogenet.  Cell Genet.  36:525- 
531. 
37.  Yang, F., J.  B.  Lum, J.  R.  McGill, C.  M.  Moore,  S.  L.  Naylor, P.  H. 
van Bragt, W. D. Baldwin, and B. H. Bowman.  1984. Human transferrin: 
cDNA characterization  and chromosomal localization. Proc. Natl. Acad. 
Sci.  USA.  81:2752-2756. 
The Journal of Cell Biology, Volume 111, 1990  1392 